galantamine has been researched along with oxytocin in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Adams, HA; Blanchard, JJ; Buchanan, RW; Carpenter, WT; Cohen, AS; Gold, J; Kelly, DL; McMahon, RP; Mitchell, KR; Strauss, GP | 1 |
| Buchanan, RW; Carpenter, WT; Gold, JM; Kelly, DL; Koola, MM; McMahon, RP; Strauss, GP; Weiner, E | 1 |
| Allam, M; El-Ganainy, SO; Elbahnasi, AI; Ghazy, AA; Gowayed, MA; Mansour, AM; Soliman, OA | 1 |
1 review(s) available for galantamine and oxytocin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for galantamine and oxytocin
| Article | Year |
|---|---|
The effects of oxytocin and galantamine on objectively-defined vocal and facial expression: Data from the CIDAR study.
Topics: Adult; Antipsychotic Agents; Facial Expression; Galantamine; Humans; Interpersonal Relations; Interview, Psychological; Middle Aged; Neuropsychological Tests; Oxytocin; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Social Behavior; Speech Production Measurement; Treatment Outcome; Video Recording; Voice; Young Adult | 2017 |
A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia.
Topics: Administration, Intranasal; Adult; Cognitive Dysfunction; Double-Blind Method; Female; Galantamine; Humans; Male; Middle Aged; Nootropic Agents; Oxytocics; Oxytocin; Pessimism; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2017 |
1 other study(ies) available for galantamine and oxytocin
| Article | Year |
|---|---|
Intranasal Oxytocin Attenuates Cognitive Impairment, β-Amyloid Burden and Tau Deposition in Female Rats with Alzheimer's Disease: Interplay of ERK1/2/GSK3β/Caspase-3.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Caspase 3; Cognitive Dysfunction; Disease Models, Animal; Female; Galantamine; Glycogen Synthase Kinase 3 beta; MAP Kinase Signaling System; Oxytocin; Rats; tau Proteins | 2022 |